CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
18 Março 2024 - 9:00AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated, localized biologics, today announced that
the first clinical candidate in its TCB agreement with Astellas has
entered into GLP toxicology studies which triggers a $5 million
payment to CytomX. The clinical candidate is the first PROBODY® TCB
molecule under this alliance to progress into a GLP toxicology
study. CytomX and Astellas are also collaborating on additional
conditionally activated TCB programs with CytomX eligible to
receive future preclinical, clinical and commercial milestones.
CytomX retains a cost share and co-commercialization option on a
select number of targets.
“We are excited by the continued momentum
towards a potential future IND for the first PROBODY® TCB clinical
candidate in our collaboration with Astellas, and we continue to
partner with Astellas on multiple preclinical programs. The
progress with this collaboration highlights the benefits of our
strategy to create value through both wholly-owned and partnered
programs, as well as the potential of our expanding pipeline of
PROBODY T-cell engagers which are designed to localize T-cell
activity to the tumor microenvironment,” said Sean McCarthy,
D.Phil., chief executive officer and chairman of CytomX
Therapeutics.
About CytomX
TherapeuticsCytomX is a clinical-stage, oncology-focused
biopharmaceutical company focused on developing novel conditionally
activated biologics designed to be localized to the tumor
microenvironment. By pioneering a novel pipeline of localized
biologics, powered by its PROBODY® therapeutic platform, CytomX’s
vision is to create safer, more effective therapies for the
treatment of cancer. CytomX’s robust and differentiated pipeline
comprises therapeutic candidates across multiple treatment
modalities including antibody-drug conjugates (“ADCs”), T-cell
engagers, and immune modulators such as cytokines. CytomX’s
clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904
is a conditionally activated T-cell-engaging antibody targeting the
epidermal growth factor receptor (EGFR) on tumor cells and the CD3
receptor on T cells and partnered with Amgen in a global
co-development alliance. CX-2051 is a conditionally activated ADC
directed toward epithelial cell adhesion molecule, EpCAM, with
potential applicability across multiple EpCAM-expressing epithelial
cancers. CX-801 is an interferon alpha-2b PROBODY® cytokine with
broad potential applicability in traditionally immuno-oncology
sensitive as well as insensitive (cold) tumors. CytomX has
established strategic collaborations with multiple leaders in
oncology, including Amgen, Astellas, Bristol Myers Squibb,
Regeneron and Moderna. For more information about CytomX and how it
is working to make conditionally activated treatments the new
standard-of-care in the fight against cancer,
visit www.cytomx.com and follow us
on LinkedIn and X
(formerly Twitter).
CytomX Therapeutics Forward-Looking
StatementsThis press release includes forward-looking
statements. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors that are
difficult to predict, may be beyond our control, and may cause the
actual results, performance, or achievements to be materially
different from any future results, performance or achievements
expressed or implied in such statements, including those related to
the future potential of partnerships or collaboration agreements.
Accordingly, you should not rely on any of these forward-looking
statements, including those relating to the potential benefits,
safety and efficacy or progress of CytomX’s or any of its
collaborative partners’ product candidates, including CX-2051,
CX-801, and CX-904, the potential benefits or applications of
CytomX’s PROBODY® therapeutic platform, CytomX’s or its
collaborative partners’ ability to develop and advance product
candidates into and successfully complete clinical trials,
including the ongoing and planned clinical trials of CX-904, and
the timing of the commencement of clinical trials or initial and
ongoing data availability for CX-801 and CX-2051, and other
development milestones. Risks and uncertainties that contribute to
the uncertain nature of the forward-looking statements include: the
unproven nature of CytomX’s novel PROBODY® therapeutic technology;
CytomX’s clinical trial product candidates are in the initial
stages of clinical development and its other product candidates are
currently in preclinical development, and the process by which
preclinical and clinical development could potentially lead to an
approved product is long and subject to significant risks and
uncertainties, including the possibility that the results of
preclinical research and early clinical trials may not be
predictive of future results; the possibility that CytomX’s
clinical trials will not be successful; the possibility that
current preclinical research may not result in additional product
candidates; CytomX’s dependence on the success of CX-904, CX-801,
and CX-2051; CytomX’s reliance on third parties for the manufacture
of the Company’s product candidates; possible regulatory
developments in the United States and foreign countries; and the
risk that we may incur higher costs than expected for research and
development or unexpected costs and expenses. Additional applicable
risks and uncertainties include those relating to our preclinical
research and development, clinical development, and other risks
identified under the heading "Risk Factors" included in CytomX’s
Annual Report on Form 10-K filed with the SEC on March 11, 2024.
The forward-looking statements contained in this press release are
based on information currently available to CytomX and speak only
as of the date on which they are made. CytomX does not undertake
and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
PROBODY is a U.S. registered trademark of CytomX
Therapeutics, Inc.
Investor Contact:Chris
OgdenSVP, Finance and Accountingcogden@cytomx.com
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com
CytomX Therapeutics (NASDAQ:CTMX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024